145 related articles for article (PubMed ID: 22943430)
1. Large-cell neuroendocrine carcinoma with epidermal growth factor receptor mutation: possible transformation of lung adenocarcinoma.
Yanagisawa S; Morikawa N; Kimura Y; Nagano Y; Murakami K; Tabata T
Respirology; 2012 Nov; 17(8):1275-7. PubMed ID: 22943430
[No Abstract] [Full Text] [Related]
2. A patient with simultaneously appearing adenocarcinoma and small-cell lung carcinoma harbouring an identical EGFR exon 19 mutation.
van Riel S; Thunnissen E; Heideman D; Smit EF; Biesma B
Ann Oncol; 2012 Dec; 23(12):3188-3189. PubMed ID: 23079729
[No Abstract] [Full Text] [Related]
3. Histological Transformation to Large Cell Neuroendocrine Carcinoma from Lung Adenocarcinoma Harboring an EGFR Mutation: An Autopsy Case Report.
Moriya R; Hokari S; Shibata S; Koizumi T; Tetsuka T; Ito K; Hashidate H; Tsukada H
Intern Med; 2017; 56(15):2013-2017. PubMed ID: 28768973
[TBL] [Abstract][Full Text] [Related]
4. Large-cell neuroendocrine carcinoma of the lung harboring EGFR mutation and responding to gefitinib.
De Pas TM; Giovannini M; Manzotti M; Trifirò G; Toffalorio F; Catania C; Spaggiari L; Labianca R; Barberis M
J Clin Oncol; 2011 Dec; 29(34):e819-22. PubMed ID: 22042963
[No Abstract] [Full Text] [Related]
5. Traditional Chinese medicine herbal treatment may have a relevant impact on the prognosis of patients with stage IV adenocarcinoma of the lung treated with platinum-based chemotherapy or combined targeted therapy and chemotherapy.
Guo H; Liu JX; Xu L; Madebo T; Baak JP
Integr Cancer Ther; 2011 Jun; 10(2):127-37. PubMed ID: 21147812
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis.
Kang EJ; Min KH; Hur GY; Lee SY; Shim JJ; Kang KH; Oh SC; Seo JH; Kim JS
Chemotherapy; 2016; 61(1):41-50. PubMed ID: 26517706
[TBL] [Abstract][Full Text] [Related]
7. Marked response to nab-paclitaxel in EGFR mutated lung neuroendocrine carcinoma: A case report.
Liang JY; Tong F; Gu FF; Liu YY; Zeng YL; Hong XH; Zhang K; Liu L
Medicine (Baltimore); 2017 May; 96(21):e6985. PubMed ID: 28538405
[TBL] [Abstract][Full Text] [Related]
8. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.
Fichtner I; Rolff J; Soong R; Hoffmann J; Hammer S; Sommer A; Becker M; Merk J
Clin Cancer Res; 2008 Oct; 14(20):6456-68. PubMed ID: 18927285
[TBL] [Abstract][Full Text] [Related]
9. Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study.
Ranson M; Reck M; Anthoney A; Hanauske AR; Dean E; Melezinek I; Klingelschmitt G; Kletzl H; Blatter J; Twelves C
Ann Oncol; 2010 Nov; 21(11):2233-2239. PubMed ID: 20444843
[TBL] [Abstract][Full Text] [Related]
10. Transformation into large-cell neuroendocrine carcinoma associated with acquired resistance to erlotinib in nonsmall cell lung cancer.
Lim JU; Woo IS; Jung YH; Byeon JH; Park CK; Kim TJ; Kim HR
Korean J Intern Med; 2014 Nov; 29(6):830-3. PubMed ID: 25378985
[No Abstract] [Full Text] [Related]
11. Combined large cell neuroendocrine carcinoma and adenocarcinoma with epidermal growth factor receptor mutation in a female patient who never smoked.
Yoshida Y; Ota S; Murakawa T; Takai D; Nakajima J
Ann Thorac Cardiovasc Surg; 2014; 20 Suppl():582-4. PubMed ID: 23518631
[TBL] [Abstract][Full Text] [Related]
12. Germ-line and somatic presentations of the EGFR T790M mutation in lung cancer.
Prudkin L; Tang X; Wistuba II
J Thorac Oncol; 2009 Jan; 4(1):139-41. PubMed ID: 19096324
[No Abstract] [Full Text] [Related]
13. Discordant HER2 Exon 20 Mutation Status Determines a Differential Sensitivity to Afatinib.
Gow CH; Liao WY; Liu YN; Shih JY
J Thorac Oncol; 2015 Jul; 10(7):e58-60. PubMed ID: 26134234
[No Abstract] [Full Text] [Related]
14. Gemcitabine concurrent with thoracic radiotherapy after induction chemotherapy with gemcitabine/vinorelbine in locally advanced non-small cell lung cancer: a phase I study.
Gagel B; Piroth M; Pinkawa M; Reinartz P; Zimny M; Fischedik K; Stanzel S; Breuer C; Skobel E; Asadpour B; Schmachtenberg A; Buell U; Eble MJ
Strahlenther Onkol; 2006 May; 182(5):263-9. PubMed ID: 16673059
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor mutations are associated with docetaxel sensitivity in lung cancer.
Yoshimasu T; Oura S; Ohta F; Hirai Y; Naito K; Nakamura R; Nishiguchi H; Hashimoto S; Kawago M; Okamura Y
J Thorac Oncol; 2011 Oct; 6(10):1658-62. PubMed ID: 21681119
[TBL] [Abstract][Full Text] [Related]
16. Favorable response to gefitinib treatment of lung adenocarcinoma with coexisting germline and somatic epidermal growth factor receptor mutations.
Chung KP; Shih JY; Yu CJ
J Clin Oncol; 2010 Dec; 28(34):e701-3. PubMed ID: 20823418
[No Abstract] [Full Text] [Related]
17. Lung carcinomas with EGFR exon 19 insertions are sensitive to gefitinib treatment.
Iyevleva AG; Mitiushkina NV; Karaseva NA; Orlov SV; Volodina LN; Kulikova YE; Lozhkina AM; Ivantsov AO; Tiurin VI; Togo AV; Imyanitov EN
J Thorac Oncol; 2014 Apr; 9(4):e31-3. PubMed ID: 24736087
[No Abstract] [Full Text] [Related]
18. Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale.
Gebbia V; Galetta D; Caruso M; Verderame F; Pezzella G; Valdesi M; Borsellino N; Pandolfo G; Durini E; Rinaldi M; Loizzi M; Gebbia N; Valenza R; Tirrito ML; Varvara F; Colucci G;
Lung Cancer; 2003 Feb; 39(2):179-89. PubMed ID: 12581571
[TBL] [Abstract][Full Text] [Related]
19. A novel point mutation in exon 20 of EGFR showed sensitivity to erlotinib.
Xing K; Zhou X; Zhao X; Sun S; Luo Z; Wang H; Yu H; Wang J; Chang J; Wu X; Hu A
Med Oncol; 2014 Jul; 31(7):36. PubMed ID: 24908064
[TBL] [Abstract][Full Text] [Related]
20. Coexistence of tyrosine kinase inhibitor-sensitizing and resistant EGFR mutations in an untreated lung adenocarcinoma patient and response to erlotinib.
Mathur G; Ma D
J Thorac Oncol; 2014 Jul; 9(7):e55-e57. PubMed ID: 24926557
[No Abstract] [Full Text] [Related]
[Next] [New Search]
